

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:57:53 ON 17 JUN 2009

=> b reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:58:02 ON 17 JUN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3

DICTIONARY FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1992 AND 2006 AND 2016

L1 SCREEN CREATED

=>

Uploading C:\Documents and Settings\jlau1\My Documents\10581144 - HDMAPP\2nd\genus 2.str



chain nodes :
 1 2 3 4 5 6 7 8 10 11 12 13 18
 chain bonds :
 1-2 1-18 2-3 2-6 3-4 4-5 4-7 4-8 5-10 10-11 10-12 10-13
 exact/norm bonds :
 1-18 2-3 2-6 3-4 4-5 4-7 4-8 5-10 10-11 10-12 10-13
 exact bonds :
 1-2

G1:CH,N

G2:O,N

G3:Ar,H


G4:OH,COOH,CHO,C(O)CH3

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 18:CLASS

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L2 STR



G4 OH, COOH, CHO, C(O)CH₃

L3 OUE ABB=ON PLU=ON L2 AND L1

SAMPLE SCREEN SEARCH COMPLETED - 632 TO ITERATE

0 ANSWERS

SEARCH TIME: 00.00.01

BATCH **COMPLETE**

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L2 AND L1

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.48 0.70

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:58:38 ON 17 JUN 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajs11623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 10:27:59 ON 17 JUN 2009
FILE 'REGISTRY' ENTERED AT 10:27:59 ON 17 JUN 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

=> d his

(FILE 'HOME' ENTERED AT 08:57:53 ON 17 JUN 2009)

FILE 'REGISTRY' ENTERED AT 08:58:02 ON 17 JUN 2009

L1 SCREEN 1992 AND 2006 AND 2016
L2 STRUCTURE UPLOADED
L3 QUE L2 AND L1
L4 0 S L3 SSS SAM

=> s l3 sss full

FULL SEARCH INITIATED 10:28:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12489 TO ITERATE

100.0% PROCESSED 12489 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L5 2 SEA SSS FUL L2 AND L1


=> d l5 1-2

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 853682-73-2 REGISTRY
ED Entered STN: 03 Jul 2005
CN Amidodiphosphoric acid, N-[(2E)-4-hydroxy-3-methyl-2-buten-1-yl]- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Amidodiphosphoric acid, [(2E)-4-hydroxy-3-methyl-2-butenyl]- (9CI)
FS STEREOSEARCH
MF C5 H13 N O7 P2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 853402-91-2 REGISTRY
ED Entered STN: 30 Jun 2005

CN Amidodiphosphoric acid, [(2E)-4-hydroxy-3-methyl-2-butenyl]-, trisodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C5 H13 N O7 P2 . 3 Na
SR CA
LC STN Files: CA, CAPLUS
CRN (853682-73-2)

Double bond geometry as shown.



● 3 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

190.94

191.16

FILE 'CAPLUS' ENTERED AT 10:29:11 ON 17 JUN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2009 VOL 150 ISS 25

FILE LAST UPDATED: 15 Jun 2009 (20090615/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15

L6 4 L5

=> d 16 1-4 ibib abs hitstr

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1455006 CAPLUS

DOCUMENT NUMBER: 150:16057

TITLE: Improved methods of using phosphoantigens for the treatment of cancer

INVENTOR(S): Sicard, Helene

PATENT ASSIGNEE(S): Innate Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 66pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008146167	A2	20081204	WO 2008-IB2197	20080521
WO 2008146167	A3	20090312		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-941441P P 20070601

AB The present invention provides novel approaches and strategies for efficient regulation of $\gamma\delta$ T cells in vivo, in a subject, particularly a human subject or a non-human primate. The present invention discloses particular compns. and methods that can be used to induce the proliferation of $\gamma\delta$ T cells in vivo. These compns. and methods employ the conjoint treatment of an individual with a $\gamma\delta$ T cell activating compound and IL-2 and are particularly suited for immunotherapy in a subject, particularly in a subject having cancer or an infectious disease.

IT **853682-73-2**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(improved methods of using phosphoantigens for the treatment of cancer)

RN 853682-73-2 CAPLUS

CN Amidodiphosphoric acid, N-[(2E)-4-hydroxy-3-methyl-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:614166 CAPLUS

DOCUMENT NUMBER: 148:577360

TITLE: Improved methods of using phosphoantigen for the treatment of cancer

INVENTOR(S): Tiollier, Jerome; Sicard, Helene; Bonnafeous, Cecile

PATENT ASSIGNEE(S): Innate Pharma, Fr.

SOURCE: PCT Int. Appl., 107pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008059052	A1	20080522	WO 2007-EP62456	20071116
WO 2008059052	A9	20090312		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
WO 2007057440	A2	20070524	WO 2006-EP68610	20061117
WO 2007057440	A3	20080403		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: WO 2006-EP68610 A 20061117

US 2007-938020P P 20070515

US 2005-737588P P 20051117

AB The present invention relates to compns. and methods useful for treating a cancer in mammals, including humans. The methods and compns. typically comprise use of a chemotherapeutic agent and a $\gamma\delta$ T cell activator, such that the composition is effective for treating a cancer.

Preferably the composition enhances the effect of the T cell activator and/or prevents or delays the escape of a tumor from control chemotherapy, particularly an anti-angiogenic chemotherapeutic agent.

IT 853682-73-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(improved methods of using phosphoantigen for treatment of cancer with $\gamma\delta$ T cell activator in combination with chemotherapeutic agent)

RN 853682-73-2 CAPLUS

CN Amidodiphosphoric acid, N-[(2E)-4-hydroxy-3-methyl-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:71311 CAPLUS

DOCUMENT NUMBER: 148:142876

TITLE: Methods and compositions for increasing the efficiency of therapeutic antibodies using $\gamma\delta$ T cell activators

INVENTOR(S): Fournie, Jean-Jacques; Gertner, Julie; Sicard, Helene

PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.; Innate Pharma S.A.

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006895	A2	20080117	WO 2007-EP57217	20070712
WO 2008006895	A3	20080327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1878440	A1	20080116	EP 2006-291146	20060713
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,			

BA, HR, MK, YU
AU 2007274295 A1 20080117 AU 2007-274295 20070712
CA 2658222 A1 20080117 CA 2007-2658222 20070712
EP 2040750 A2 20090401 EP 2007-765821 20070712
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.: EP 2006-291146 A 20060713
US 2007-924208P P 20070503
WO 2007-EP57217 W 20070712

OTHER SOURCE(S): MARPAT 148:142876

AB The authors disclose the use of a therapeutic antibody in combination with a $\gamma\delta$ + T-cell-activating compound or activated $\gamma\delta$ + T-cells for potentiation of $\gamma\delta$ + T-cell cytotoxicity against targeted cells. In one example, phosphoantigen-activated $\gamma\delta$ + T-cells were shown to enhance the therapeutic efficacy of Rituximab against breast cancer cells.

IT **853682-73-2**


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

($\gamma\delta$ + T-cell activators increase efficacy of therapeutic antibodies)

RN 853682-73-2 CAPLUS

CN Amidodiphosphoric acid, N-[(2E)-4-hydroxy-3-methyl-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523468 CAPLUS

DOCUMENT NUMBER: 143:43970

TITLE: New class of gamma delta t cells activators and use thereof

INVENTOR(S): Belmant, Christian; Nury, Patrice

PATENT ASSIGNEE(S): Innate Pharma, Fr.

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054258	A2	20050616	WO 2004-IB4311	20041202
WO 2005054258	A3	20060309		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 WO 2004050096 A2 20040617 WO 2003-IB6375 20031202
 WO 2004050096 A3 20040916
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2004295194 A1 20050616 AU 2004-295194 20041202
 CA 2547008 A1 20050616 CA 2004-2547008 20041202
 EP 1689758 A2 20060816 EP 2004-806475 20041202
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU
 CN 1890252 A 20070103 CN 2004-80035657 20041202
 BR 2004017088 A 20070313 BR 2004-17088 20041202
 JP 2007516244 T 20070621 JP 2006-542053 20041202
 IN 2006DN02826 A 20070803 IN 2006-DN2826 20060518
 MX 2006006327 A 20061211 MX 2006-6327 20060602
 US 20070249565 A1 20071025 US 2007-581144 20070705
 PRIORITY APPLN. INFO.: WO 2003-IB6375 A 20031202
 US 2004-579237P P 20040615
 EP 2002-292963 A 20021202
 US 2004-579237 A 20040615
 WO 2004-IB4311 W 20041202
 OTHER SOURCE(S): CASREACT 143:43970; MARPAT 143:43970
 GI



I

AB The present invention relates to a new class of compds., I (Cat+ = organic or mineral cation, H; m = 1-3; B = O, NH, any group capable of hydrolyzing; Y = O-Cat+, C1-3 alkyl, group consisting of nucleoside, oligonucleotide, nucleic acid, amino acid, peptide, protein, monosaccharide, etc.; R = linear, branched, cyclic, aromatic, (un)saturated C1-50 hydrocarbon, etc.), having $\gamma\delta$ T cells activating properties, a composition comprising these compds. and methods for regulating an immune response in a subject comprising the step of administering these compds. Thus, (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphoramidate is prepared in 6 steps

starting from 2-methyl-2-vinyloxirane. Bioactivity of the compds. prepared is given.

IT **853682-73-2**


RL: PRPH (Prophetic)

(New class of gamma delta t cells activators and use thereof)

RN 853682-73-2 CAPLUS

CN Amidodiphosphoric acid, N-[(2E)-4-hydroxy-3-methyl-2-buten-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



IT **853402-91-2P**


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrophosphoramidates as new class of gamma delta t cells activators)

RN 853402-91-2 CAPLUS

CN Amidodiphosphoric acid, [(2E)-4-hydroxy-3-methyl-2-butenyl]-, trisodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●3 Na

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b marpat

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.06

214.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28

-3.28

FILE 'MARPAT' ENTERED AT 10:29:46 ON 17 JUN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 23 (20090612/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090117607 07 MAY 2009
DE 102007051339 30 APR 2009
EP 2050761 22 APR 2009
JP 2009088302 23 APR 2009
WO 2009061597 14 MAY 2009
GB 2453808 22 APR 2009
FR 2922550 24 APR 2009
RU 2353629 27 APR 2009
CA 2605026 28 MAR 2009

The new MARPAT User Guide is now available at:
<http://www.cas.org/support/stngen/stdoc/marpat.html>.

=> s l5 sss sam

QUERY CONTAINS NON-SEARCHABLE SCREENS IN L1.

ONLY STRUCTURE L2 WILL BE SEARCHED.

STRUCTURE TOO LARGE - SEARCH ENDED

A structure in your query is too large. You may delete
attributes or atoms to reduce the size of the structure
and try again.

=> d his

(FILE 'HOME' ENTERED AT 08:57:53 ON 17 JUN 2009)

FILE 'REGISTRY' ENTERED AT 08:58:02 ON 17 JUN 2009

L1 SCREEN 1992 AND 2006 AND 2016

L2 STRUCTURE UPLOADED

L3 QUE L2 AND L1

L4 0 S L3 SSS SAM

L5 2 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:29:11 ON 17 JUN 2009


L6 4 S L5

FILE 'MARPAT' ENTERED AT 10:29:46 ON 17 JUN 2009

=> d l2

L2 HAS NO ANSWERS

L2 STR



G1 CH,N

G2 O,N

G3 Ak,H

G4 OH,COOH,CHO,C(O)CH3

Structure attributes must be viewed using STN Express query preparation.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.44

215.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.28

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:31:31 ON 17 JUN 2009